Current Report · Items 2.02, 9.01 · 8-K

Geron Corporation

GERNNASDAQEQUITYCurrent

Results of Operations and Financial Condition

Filed Feb 25, 2026Accepted Feb 25, 2026, 7:15 AM ESTCIK 886744Accession 0001193125-26-068523

Company context

Geron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor RYTELO® (imetelstat) is approved in the United States and the European Union for the treatment of certain adult patients with lower-risk myelodysplastic syndromes with transfusion dependent anemia. We are also conducting a pivotal Phase 3 clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis, as well as studies in other hematologic malignancies. To learn more, visit www.geron.com or follow us on LinkedIn.

Current securities

GERNNASDAQ · EQUITY · Current

Historical securities (1)

GERNWOTC · WARRANT · Historical · closed Dec 30, 2025

Recent company filings

Disclosure sections

Items 2.02, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 2.02Item 2.02 - Results of Operations

Item 2.02 Results of Operations and Financial Condition On February 25, 2026, Geron Corporation (the “Company”) issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2025 and recent business highlights. A copy of the press release is attached as Exhibit 99.1. The information contained in Item 2.02 and in the accompanying Exhibit 99.1 to this Current Report shall be deemed to be “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and shall not be incorporated by reference into any filing made by the Company with the U.S. Securities and Exchange Commission under the Securities Act or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Filed exhibits (1)

EX-99.1 (by filename) d67820dex991.htm

EX-99.1 2 d67820dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Geron Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights Achieved $48 million and $184 million in RYTELO ® (imetelstat) net product revenue in Q4 2025 and full year 2025, respectively Reported total operating expenses of $255 million for full year 2025, within the previous guidance range Reiterated 2026 RYTELO net product revenue and total operating expenses expected in the ranges of $220 million to $240 million, and $230 million to $240 million, respectively Ended 2025 with cash, cash equivalents, restricted cash and marketable securities of roughly $401 million Company to host conference call and webcast today, February 25, at 8:00 a.m. ET FOSTER CITY, Calif., February 25, 2026 - Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported financial results for the fourth quarter and full year of 2025 and recent business highlights. “Strategic actions we have taken in the second half of 2025 position Geron to drive RYTELO demand growth and invest to create value whil…

Open exhibit ↗